Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BioVAT-HF: EHM Implantation in Terminal Heart Failure
NCT04396899Phase 2Recruiting
- Sponsor
- Universitätsmedizin Göttingen
- Start
- Feb 2020
- Primary completion
- Dec 2027
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial in heart failure (HF), sponsored by Universitätsmedizin Göttingen. Primary endpoints: Adverse events at 12 months, Heart target heart wall thickness at 12 months and 2 more. Started Feb 2020; status: recruiting.
02
Conditions
heart failure (HF)
Beyond the preview
Go deeper on NCT04396899.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04396899.